News
Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic, Improves Epithelial Barrier Function and Promotes Mucosal Healing in Inflammatory Bowel Disease
May 24, 2022, BRISBANE, CA
Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1) Activity
April 8, 2022, BRISBANE, CA
Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration
March 2, 2022, BRISBANE, CA
Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)
February 24, 2022, BRISBANE, CA
Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of European Crohn’s and Colitis Organization (ECCO)
February 18, 2022, BRISBANE, CA
Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23
February 14, 2022, BRISBANE, CA
Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)
February 10, 2022, BRISBANE, CA
Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer
January 19, 2022, BRISBANE, CA